Cordis recently announced the first-in-human use of the Radianz radial peripheral system by Jihad Mustapha at Advanced Cardiac & Vascular Centers (ACV) in Grand Rapids, USA. 

Artio Medical today announced the closing of US$28 million in oversubscribed Series A2 and Series A3 financing, bringing the total amount raised by the company to date to US$74 million.

M.I.Tech is the creator of the HANAROSTENT technology, a family of conformable, non-vascular, self-expanding metal stents, which have been distributed by Boston Scientific in Japan since 2015. The agreement consists of a purchase price of KRW 14,500 per share, which represents a total of KRW 291.2 billion or approximately $230 million at current exchange rates, subject to closing adjustments.

Data from the first report on patients with a pacemaker lead across the tricuspid valve have shown that implant of the TriClip and TriClip G4 transcatheter edge-to-edge repair (TEER) systems (Abbott) significantly reduces tricuspid regurgitation (TR) and improves quality of life.

Royal Philips today announced the latest results from the Tack optimised balloon angioplasty (TOBA) II below-the-knee (BTK) clinical trial, demonstrating that the Philips endovascular system—Tack (4F)—provides a sustained treatment effect and positive impact on quality of life for patients with chronic limb-threatening ischaemia (CLTI) out to three years of clinical follow-up. The Tack 4F is the first and only device of its kind approved by the US Food and Drug Administration (FDA), according to a company press release.

Based on over four years of experience in a single centre, Robert Shahverdyan (Asklepios Klinik Barmbek, Hamburg, Germany) claims that endovascular arteriovenous fistula (endoAVF) creation “keeps future options open,” but is not a replacement for surgical fistula creation.

Arjo has announced the development of a new intraoperative Doppler system that includes a single-use, sterile intraoperative probe and Dopplex DMX Vascular Doppler.

AtriCure has announced that the first patient has been treated in the HEAL-IST trial, evaluating the safety and effectiveness of AtriCure’s Isolator Synergy Clamp for the treatment of drug-refractory patients diagnosed with inappropriate sinus tachycardia (IST). The first patient was treated by Mark LaMeir and Carlo de Asmundis at University Hospital Brussels, Brussels, Belgium.

A retrospective review of more than 24,000 patients who underwent an electrocardiogram (ECG) has found that nearly one-quarter had mitral annulus calcification. Researchers from Mayo Clinic (Rochester, USA), who carried out the study, reported that mitral valve dysfunction was more than twice as prevalent for those patients, who also were at higher risk of all-cause mortality.

Filterlex Medical has announced results from a first-in-human (FIH) study demonstrating the safety, feasibility, and performance of the Captis device, a full-body embolic protection device that reduces risk of stroke and other complications during left-heart procedures.

Transcatheter aortic valve implantation (TAVI) was found to be non-inferior to surgery for all-cause mortality at one year among patients aged 70 years or older with severe, symptomatic aortic stenosis and moderately increased operative risk according to findings of the UK TAVI trial, published in the Journal of the American Medical Association (JAMA) this mont

Concurrent tricuspid valve surgery and left ventricular assist device (LVAD)  implantation did not lead to a lower incidence of right heart failure (RHF) when compared to LVAD implantation alone in these select patients.